- 4D Molecular Therapeutics Inc 4D-150 Phase 2 PRISM Clinical Data Call TranscriptFeb 05, 2024
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data and Program Update Call TranscriptNov 01, 2023
- 4D Molecular Therapeutics Inc at Chardan Genetic Medicines Conference TranscriptOct 02, 2023
- 4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- 4D Molecular Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data Call TranscriptJun 07, 2023
- 4D Molecular Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- 4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- 4D Molecular Therapeutics Inc 4D-150 Phase 1/2 PRISM Interim Clinical Data - Corporate Call TranscriptApr 27, 2023
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 Interim Clinical Data Call TranscriptFeb 22, 2023
- 4D Molecular Therapeutics Inc Phase 1/2 Clinical Trial of 4D-150 for Wet AMD - Corporate Call TranscriptNov 14, 2022
- 4D Molecular Therapeutics Inc Interim Clinical Data Presented at NACFC - Corporate Call TranscriptNov 03, 2022
- 4D Molecular Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- 4D Molecular Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 and 4D-110 Phase 1/2 Clinical Data Update Call TranscriptOct 25, 2021
4D Molecular Therapeutics Inc 4D-310 Phase 1/2 and 4D-110 Phase 1/2 Clinical Data Update Call Transcript
Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics 4D-310 and 4D-110 Clinical Data Conference Call. (Operator Instructions) As a reminder, today's call is being recorded. With that, I will hand over the call to Mike Zanoni, Vice President, Head of Investor Relations, who will make introductory comments.
Thank you, Van, and welcome, everyone, to 4D Molecular Therapeutics 4D-310 and 4D-110 Clinical Data Conference Call. Today's webcasted presentation as well as this afternoon's press release describing the initial results from our Phase I/II clinical study of 4D-310 in patients with Fabry disease as well as an update on the 4D-110 choroideremia Phase I/II clinical trial are accessible in the Investors section of the 4D Molecular Therapeutics website.
With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; Dr. Robert Fishman, our Chief Medical Officer; Dr. [Rafi] Schiffmann, our SVP and Clinical Therapeutic Area Head, Lysosomal Storage Diseases and Cardiology; and Augie Moretti,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)